Imphal News Flash

DelveInsight, a leading market research firm, has released its latest report, “DelveInsight’s Chronic Myeloid Leukemia (CML) Market Insights, Epidemiology, and Market Forecast 2034.” The report provides a comprehensive understanding of CML, including historical and forecasted epidemiology, market trends, current treatment landscape, and emerging therapies across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Key Takeaways from the Chronic Myeloid Leukemia (CML) Market

• The Chronic Myeloid Leukemia market size in the 7MM is expected to grow significantly during the forecast period (2025–2034).

• The United States accounted for the largest CML market size among the 7MM in 2025, compared to EU4 countries, the United Kingdom, and Japan.

• According to DelveInsight’s estimates, the CML market size in the 7MM was approximately USD 235 million in 2020, which is projected to increase significantly by 2034.

• According to SEER, the number of new CML cases in the US is expected to be around 9,560 in 2025.

• According to the American Cancer Society, approximately 9,560 new cases of CML are expected to be diagnosed in the United States in 2025, including 5,610 cases in men and 3,950 cases in women.

• As per the SEER database, the rate of new CML cases was 2.0 per 100,000 men and women per year based on 2018–2022 cases.

• According to the study conducted by Qingqing Lin et al. (2020), approximately 34,179 incident cases of CML and 24,054 CML-related deaths were reported globally in 2017.

• According to the study by Elias Jabbour et al. (2018), CML is a myeloproliferative neoplasm with an incidence of 1–2 cases per 100,000 adults.

• Leading CML companies such as Enliven Therapeutics, Terns Pharmaceuticals, Ascentage Pharma, Takeda Pharmaceuticals, AOP Orphan Pharmaceuticals, Novartis, and others are developing novel therapies for the treatment of CML.

• Promising therapies in the CML pipeline include ELVN-001, TERN-701, olverembatinib (HQP1351), BESREMi (ropeginterferon alfa 2b), and others.

Want to know more about the market? Visithttps://www.delveinsight.com/sample-request/chronic-myeloid-leukemia-market

Key Factors Driving the Chronic Myeloid Leukemia (CML) Market

• Increasing Incidence of CML: Rising incident cases of CML globally are contributing significantly to market growth.

• Advancements in Targeted Therapies: The development and adoption of next-generation tyrosine kinase inhibitors (TKIs) with improved efficacy and tolerability profiles are transforming CML treatment paradigms.

• Growing Demand for Personalized Treatment Approaches: Regular molecular testing and mutation profiling are improving therapy selection and treatment outcomes.

• Emergence of Novel Therapies: Pipeline candidates such as ELVN-001, TERN-701, and olverembatinib are expected to improve treatment outcomes in resistant or intolerant CML patients.

• Improved Diagnostic Technologies: Increasing use of cytogenetic analysis, FISH, and RT-PCR testing for BCR-ABL1 detection is supporting early diagnosis and treatment optimization.

Chronic Myeloid Leukemia (CML) Competitive Landscape

• Several emerging therapies are currently under clinical development for the treatment of CML, including ELVN-001, TERN-701, olverembatinib (HQP1351), BESREMi, and others.

• These therapies focus on advanced BCR-ABL inhibition mechanisms, allosteric kinase inhibition, improved selectivity, and better safety profiles to address resistance, intolerance, and long-term disease management challenges in CML patients.

Learn more about the therapies expected to capture significant CML market share @ CML Treatment Landscape

Recent Developments in the Chronic Myeloid Leukemia (CML) Market

• In November 2025, Enliven Therapeutics announced that it would present data from the ongoing ENABLE Phase Ia/Ib clinical trial of ELVN-001 in patients with atypical fusion transcript CML at the 67th ASH Annual Meeting 2025.

• In June 2025, Enliven Therapeutics presented updated positive Phase I ENABLE trial data for ELVN-001 at the European Hematology Association (EHA) 2025 Congress.

• In December 2025, Ascentage Pharma presented updated data on olverembatinib in second-line treatment of chronic-phase CML patients at ASH 2025.

• In December 2025, Terns Pharmaceuticals announced updated and expanded data from the ongoing CARDINAL trial of TERN-701 in previously treated CML patients at ASH 2025.

• In October 2024, the US FDA granted accelerated approval to asciminib for adult patients with newly diagnosed Philadelphia chromosome-positive chronic-phase CML.

• In September 2023, the US FDA approved BOSULIF for pediatric patients aged 1 year or older with chronic-phase Philadelphia chromosome-positive CML that is newly diagnosed or resistant/intolerant to prior therapy.

What is Chronic Myeloid Leukemia (CML)?

Chronic Myeloid Leukemia (CML) is a type of blood and bone marrow cancer characterized by the excessive production of abnormal white blood cells due to the presence of the BCR-ABL1 fusion gene, commonly known as the Philadelphia chromosome. CML typically progresses slowly and is classified into chronic, accelerated, and blast phases. The disease is primarily treated using tyrosine kinase inhibitors (TKIs), which target the abnormal BCR-ABL protein and help patients achieve long-term disease control.

Chronic Myeloid Leukemia (CML) Epidemiology Segmentation

The CML epidemiology section provides insights into historical and forecasted patient pools and epidemiology trends across the 7MM during the study period 2020–2034. The report segments the epidemiology into:

• Total Incident Cases of CML

• Total Symptomatic Incident Cases of CML

• Incident Cases of CML by Phases (Chronic, Accelerated, and Blast)

• Age-specific Incident Cases of CML

• Mutation-specific Incident Cases of CML

Scope of the Chronic Myeloid Leukemia (CML) Market Report

• Therapeutic Assessment: CML current and emerging therapies

• CML Market Dynamics: Key Market Forecast Assumptions and Market Outlook

• Key Companies: Enliven Therapeutics, Terns Pharmaceuticals, Ascentage Pharma, Takeda Pharmaceuticals, AOP Orphan Pharmaceuticals, Novartis, and others

• Key Therapies: ELVN-001, TERN-701, olverembatinib (HQP1351), BESREMi, SCEMBLIX, ICLUSIG, BOSULIF, and others

• Competitive Intelligence Analysis: SWOT analysis and market entry strategies

• Unmet Needs, KOL’s views, Analyst’s views, Market Access and Reimbursement

To know more about companies working in the CML treatment market, visit @ CML Clinical Trials and Emerging Therapies

Table of Contents

1. Chronic Myeloid Leukemia (CML) Market Report Introduction

2. Executive Summary of CML

3. SWOT Analysis of CML

4. CML Epidemiology and Market Forecast Methodology

5. CML Market Overview at a Glance

6. Disease Background and Overview of CML

7. CML Epidemiology and Patient Population

8. Country-specific Patient Population of CML

9. CML Current Treatment and Medical Practices

10. CML Emerging Therapies

11. CML Market Outlook

12. Country-wise CML Market Analysis (2020–2034)

13. CML Market Access and Reimbursement

14. CML Market Drivers

15. CML Market Barriers

16. Appendix

17. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve business performance. DelveInsight’s subscription-based platform PharmDelve offers seamless access to healthcare and pharma market research reports.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services